TY - JOUR
T1 - Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions
T2 - Results from the KING observational study of the Italian Society for Rheumatology (SIR)
AU - Scirè, Carlo A.
AU - Manara, Maria
AU - Cimmino, Marco A.
AU - Govoni, Marcello
AU - Salaffi, Fausto
AU - Punzi, Leonardo
AU - Monti, Maria C.
AU - Carrara, Greta
AU - Montecucco, Carlomaurizio
AU - Matucci-Cerinic, Marco
AU - Minisola, Giovanni
AU - Galossi, Alessandra
AU - Lauriti, Ciro
AU - Fracassi, Elena
AU - Selvi, Enrico
AU - Tirri, Enrico
AU - Furini, Federica
AU - Inverardi, Flora
AU - Porta, Francesco
AU - Venturino, Francesco
AU - Capsoni, Franco
AU - Sebastiani, Giandomenico
AU - Fabbriciani, Gianluigi
AU - D'Avola, Giovanni
AU - Botticella, Giulia
AU - Seminara, Giulia
AU - D'Alessandro, Giuseppe
AU - Santo, Leonardo
AU - Longato, Lorena
AU - Sinigaglia, Luigi
AU - Atteritano, Marco
AU - Broggini, Marco
AU - Caprioli, Marta
AU - Favero, Marta
AU - Sallì, Salvatore
AU - Parisi, Simone
AU - Corvaglia, Stefania
AU - Veneto, Vittorio
PY - 2013/9/3
Y1 - 2013/9/3
N2 - Introduction: Gout is the most prevalent arthritis and significantly impacts on function and quality of life. Given that gout associates with disabling comorbid conditions, it is not clear whether such a complex of diseases accounts for the increased disability or if gout may play a role by itself. This study aims to evaluate the specific influence of gout and disease-related features on functional disability and health-related quality of life (HRQoL) in patients with gout followed in rheumatology clinics.Methods: A random sample of patients was drawn from clinical registries of 30 rheumatology clinics across Italy. Sociodemographic, general health and gout-specific variables were collected. Functional disability and HRQoL were assessed by the health assessment questionnaire (HAQ) and the Physical and Mental Component Summary scores (PCS and MCS) of the Short Form-36 (SF-36). Crude and adjusted ordinal logistic and linear regression models were applied to investigate the specific contribution of different variables on HAQ and SF-36 scores. Results are presented as odds ratio (OR) or mean difference (MD) and 95% confidence intervals.Results: Out of 446 patients with gout, 90% were males with a mean age of 63.9 years and median disease duration of 3.8 years; the majority of patients were overweight or obese, and with several comorbidities; 21.1% showed at least moderate disability; the PCS score was significantly lower than expected age- and gender-matched samples in the general population, while MCS score was not. After adjusting for potential sociodemographic and general-health confounders, gout-specific variables significantly impacted on HAQ, including polyarticular involvement OR 3.82 (1.63, 8.95), presence of tophi OR 1.92 (1.07, 3.43) and recent attacks OR 2.20 (1.27, 3.81). Consistent results were found for PCS. The impairment of PCS compared to the general population was limited to patients with features of chronic gout. MCS was only affected by recent attacks (MD -2.72 [-4.58, -0.86]) and corticosteroid treatment (-3.39 [-5.30,-1.48]).Conclusions: The data from the KING study confirm that gout impacts on disability and provide evidence for an independent association of gout and gout-related features with functional outcome and HRQoL. This result supports the need to improve specific treatment in gout.
AB - Introduction: Gout is the most prevalent arthritis and significantly impacts on function and quality of life. Given that gout associates with disabling comorbid conditions, it is not clear whether such a complex of diseases accounts for the increased disability or if gout may play a role by itself. This study aims to evaluate the specific influence of gout and disease-related features on functional disability and health-related quality of life (HRQoL) in patients with gout followed in rheumatology clinics.Methods: A random sample of patients was drawn from clinical registries of 30 rheumatology clinics across Italy. Sociodemographic, general health and gout-specific variables were collected. Functional disability and HRQoL were assessed by the health assessment questionnaire (HAQ) and the Physical and Mental Component Summary scores (PCS and MCS) of the Short Form-36 (SF-36). Crude and adjusted ordinal logistic and linear regression models were applied to investigate the specific contribution of different variables on HAQ and SF-36 scores. Results are presented as odds ratio (OR) or mean difference (MD) and 95% confidence intervals.Results: Out of 446 patients with gout, 90% were males with a mean age of 63.9 years and median disease duration of 3.8 years; the majority of patients were overweight or obese, and with several comorbidities; 21.1% showed at least moderate disability; the PCS score was significantly lower than expected age- and gender-matched samples in the general population, while MCS score was not. After adjusting for potential sociodemographic and general-health confounders, gout-specific variables significantly impacted on HAQ, including polyarticular involvement OR 3.82 (1.63, 8.95), presence of tophi OR 1.92 (1.07, 3.43) and recent attacks OR 2.20 (1.27, 3.81). Consistent results were found for PCS. The impairment of PCS compared to the general population was limited to patients with features of chronic gout. MCS was only affected by recent attacks (MD -2.72 [-4.58, -0.86]) and corticosteroid treatment (-3.39 [-5.30,-1.48]).Conclusions: The data from the KING study confirm that gout impacts on disability and provide evidence for an independent association of gout and gout-related features with functional outcome and HRQoL. This result supports the need to improve specific treatment in gout.
UR - http://www.scopus.com/inward/record.url?scp=84883718269&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883718269&partnerID=8YFLogxK
U2 - 10.1186/ar4281
DO - 10.1186/ar4281
M3 - Article
C2 - 24004577
AN - SCOPUS:84883718269
VL - 15
JO - Arthritis Research and Therapy
JF - Arthritis Research and Therapy
SN - 1478-6354
IS - 5
M1 - R101
ER -